Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury.

ABSTRACT: Apigenin is the active ingredient in Ludangshen. Although previous studies reported the cardioprotective actions of apigenin against doxorubicin (Dox)-induced cardiomyopathy, the underlying mechanisms remain incompletely understood. Since apigenin beneficially regulates various aspects of mitochondrial function and dynamics, we asked whether apigenin improves heart function in mice with Dox-induced cardiomyopathy by regulating the mitochondrial unfolded protein response (UPR^mt). Co-administration of apigenin significantly restored heart function, reduced myocardial swelling, inhibited cardiac inflammation, increased cardiac transcription of UPR^mt-related genes, and promoted cardiomyocyte survival in Dox-treated mice. In turn, blockade of UPR^mt abolished the

SUBMITTER: Li H 

PROVIDER: S-EPMC10620826 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature